83 related articles for article (PubMed ID: 11217546)
1. [Mechanisms of action of BCG: towards a new individualized therapeutic approach?].
Saint F; Patard JJ; Salomon L; Alamé W; Cicco A; Abbou CC; Chopin D
Prog Urol; 2000 Dec; 10(6):1118-26. PubMed ID: 11217546
[TBL] [Abstract][Full Text] [Related]
2. [Current state of knowledge concerning the mechanisms of action of BCG].
Patard JJ; Guillé F; Lobel B; Abbou CC; Chopin D
Prog Urol; 1998 Jun; 8(3):415-21. PubMed ID: 9689679
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
[TBL] [Abstract][Full Text] [Related]
4. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
Böhle A; Brandau S
J Urol; 2003 Sep; 170(3):964-9. PubMed ID: 12913751
[TBL] [Abstract][Full Text] [Related]
5. In vitro generation of bacillus Calmette-Guérin-activated killer cells.
Brandau S; Böhle A; Thanhäuser A; Ernst M; Mattern T; Ulmer AJ; Flad HD
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S94-S100. PubMed ID: 11010832
[TBL] [Abstract][Full Text] [Related]
6. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
7. Novel insights into the mechanism of action of intravesical immunomodulators.
Mitropoulos DN
In Vivo; 2005; 19(3):611-21. PubMed ID: 15875784
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines.
Videira PA; Calais FM; Correia M; Ligeiro D; Crespo HJ; Calais F; Trindade H
Urology; 2009 Oct; 74(4):944-50. PubMed ID: 19428084
[TBL] [Abstract][Full Text] [Related]
9. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
[TBL] [Abstract][Full Text] [Related]
10. [Systemic BCG reactions after intravesical BCG therapy. A report of four cases].
Sfaxi M; Langar H; Ouni A; Riahi Y; El Aidli S; Daghfous R; Ben Abdeladhim A; Chébil M
Therapie; 2008; 63(1):43-7. PubMed ID: 18387275
[TBL] [Abstract][Full Text] [Related]
11. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
Saint F
Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
[TBL] [Abstract][Full Text] [Related]
12. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
[TBL] [Abstract][Full Text] [Related]
13. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
Andius P; Holmäng S
BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy.
Mengual L; Marín-Aguilera M; Ribal MJ; Burset M; Villavicencio H; Oliver A; Alcaraz A
Eur Urol; 2007 Sep; 52(3):752-9. PubMed ID: 17379395
[TBL] [Abstract][Full Text] [Related]
17. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer.
Bevers RF; Kurth KH; Schamhart DH
Br J Cancer; 2004 Aug; 91(4):607-12. PubMed ID: 15266312
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
19. The immune response to BCG vaccination of newborns.
Hanekom WA
Ann N Y Acad Sci; 2005 Dec; 1062():69-78. PubMed ID: 16461790
[TBL] [Abstract][Full Text] [Related]
20. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]